{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036996","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2026-08-11T12:40:21+00:00","discovered_at":"2026-08-11T12:45:00.432369+00:00","generated_at":"2026-08-11T12:45:14.448802+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"AIM ImmunoTech CEO op-ed touts Ampligen as biodefense antiviral; cites 100% Ebola survival in mouse model","bullets":["CEO Thomas K. Equels published op-ed in Breaking Defense on Aug 11, 2026 promoting Ampligen (rintatolimod) as broad-spectrum antiviral.","USAMRIID preclinical study cited: 100% survival in rintatolimod-treated Ebola mouse cohort vs 100% mortality in controls (Antiviral Research).","Company seeking government support for further Ebola/Bundibugyo and coronavirus mechanism studies; cites Utah State SARS research.","Disclosure: Ampligen not FDA-approved for Ebola, Bundibugyo, coronaviruses or any biodefense indication.","Op-ed references ~1,200 COVID infections aboard USS Theodore Roosevelt to argue for biodefense preparedness."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036996","json":"https://secwatch.observer/filing/0001493152-26-036996.json","markdown":"https://secwatch.observer/filing/0001493152-26-036996.md","text":"https://secwatch.observer/filing/0001493152-26-036996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315226036996/0001493152-26-036996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315226036996/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T12:45:14.448802+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}